Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 22, 2022

Combination of NAI and BCG found safe, effective in treatment of NMIBC

Author(s)Urology Times staff

“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.

In this interview, Karim Chamie, MD, shares interim findings from the ongoing study, “IL-15 superagonist NAI in BCG-unresponsive non–muscle-invasive bladder cancer." Chamie is an associate professor of urology at the University of California, Los Angeles.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC

ByEugene Pietzak, MD

June 22nd 2026

Sandip Prasad, MD, highlights 3-year data on mitomycin for intravesical solution for LG-IR-NMIBC

BySandip M. Prasad, MD, MPhil

June 19th 2026

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

ByAdam B. Weiner, MD,Carissa Chu, MD

June 12th 2026

Study suggests potential diuretic effect with nadofaragene firadenovec

ByAbigail Keller, MD

June 8th 2026

RAD-IO: Durvalumab plus chemoradiotherapy is feasible in MIBC

ByBenjamin P. Saylor, Strategic Content Lead

June 5th 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Trending on Urology Times

HHS requests testosterone therapy label updates, citing new safety data

Unmet needs and emerging solutions in MRI-guided prostate cancer care

Microbial dysbiosis may predict response to CBM588 in mRCC

Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD

Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC